Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

That's why many drugmakers have been looking to develop an effective oral weight loss option, and Eli Lilly might have just done it. In a phase 3 study, orforglipron, a once-daily weight ...

Industry veteran Charmaine Lykins to helm Transneural as it transforms the treatment of neuropsychiatric disorders ISSAQUAH, WASHINGTON / ACCESS Newswire / April 22, 2025 / CaaMTech, Inc. has spun out ...

"the oral GLP-1 inhibitor that we've been developing for more than eight years. And the results are exciting." On Thursday, Eli Lilly released data on Phase 3 trials of an experimental, daily ...

While Eli Lilly has a significant presence in the U.S., bringing its developing treatment to market will require stable business conditions. The Indianapolis company on Thursday said its ...